Sensus Healthcare (SRTS) Expected to Announce Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $8.3450 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 7:00 AM ET.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The firm had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. Sensus Healthcare had a negative net margin of 8.44% and a negative return on equity of 5.67%. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $5.04 on Wednesday. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.08. The company has a market capitalization of $82.76 million, a P/E ratio of -26.53 and a beta of 1.21. The business’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $3.90.

Insider Buying and Selling at Sensus Healthcare

In other Sensus Healthcare news, CEO Joseph C. Sardano bought 25,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was purchased at an average cost of $4.03 per share, with a total value of $100,750.00. Following the completion of the purchase, the chief executive officer owned 1,200,293 shares in the company, valued at approximately $4,837,180.79. The trade was a 2.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Eric Sachetta bought 7,000 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were acquired at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the purchase, the director owned 140,113 shares in the company, valued at $550,644.09. This represents a 5.26% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 36,500 shares of company stock worth $147,570. Company insiders own 8.90% of the company’s stock.

Institutional Trading of Sensus Healthcare

A hedge fund recently raised its stake in Sensus Healthcare stock. Geode Capital Management LLC increased its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 2.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 153,917 shares of the company’s stock after buying an additional 3,766 shares during the period. Geode Capital Management LLC owned 0.94% of Sensus Healthcare worth $730,000 as of its most recent filing with the SEC. 25.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on SRTS. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.